also investigated a combination treatment using siltuximab and fulvestrant, and found combination treatment to attenuate tumor growth suggesting that IL-6/JAK/STAT3 combination therapy may sensitize tumors to SOC treatment (135). This evidence concerns the gene UBXN11 and neoplasm.